menu
    • menu
    [{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Visken

    Menu

    Visken

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Actimed Therapeutics

    United Kingdom arrow
    BePharma
    Not Confirmed

    Actimed Therapeutics

    United Kingdom arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pindolol

    Therapeutic Area : Musculoskeletal

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadia...

    Details : S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.

    Product Name : ACM-001

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 13, 2021

    Lead Product(s) : Pindolol

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Actimed Therapeutics

    United Kingdom arrow
    BePharma
    Not Confirmed

    Actimed Therapeutics

    United Kingdom arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pindolol

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Undisclosed

    Deal Size : $3.4 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Actimed Therapeutics Successfully Closed of £2.5m Extended Seed B Funding Round

    Details : The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.

    Product Name : ACM-001

    Product Type : Small molecule

    Upfront Cash : Undisclosed

    June 10, 2021

    Lead Product(s) : Pindolol

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Undisclosed

    Deal Size : $3.4 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth